Since obesity is a chronic illness that can lead to type 2 diabetes, cardiovascular disease, certain cancers, and sleep disorders, the FDA responded by approving the use of semaglutide in increased dosages for treating obesity and overweight individuals with certain weight-related diseases
The FDA also said that some compounding pharmacies claiming to sell semaglutide might instead be selling other formulations of the chemical, like semaglutide sodium and semaglutide acetate
Transfer chicken to the middle of a glass baking dish
Legitimate providers source only from FDA Green List compliant suppliers
The broad, shortage-based compounding pathway ended after the FDA resolved the semaglutide and tirzepatide shortages, and in April 2026 the FDA proposed excluding these drugs from the 503B outsourcing-facility bulks list, with a comment period through June 29, 2026